Pharsight

Drugs that contain Brivaracetam

1. Briviact patents expiration

BRIVIACT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6784197 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2021

(3 years ago)

US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(1 year, 10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492416 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2021

(3 years ago)

US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Apr, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 27, 2024
New Chemical Entity Exclusivity(NCE) May 12, 2021

NCE-1 date: 12 May, 2020

Market Authorisation Date: 12 May, 2016

Treatment: Treatment of partial-onset seizures in patients 4 years of age and older

Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS

How can I launch a generic of BRIVIACT before it's drug patent expiration?
More Information on Dosage

BRIVIACT family patents

Family Patents